There were 1,728 press releases posted in the last 24 hours and 402,502 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Multi-Antigen CAR T Technology, Cell Therapy and In Vitro Diagnostics with Multiple Cancer Types: Coeptis: NASDAQ: COEP

TO:
Coeptis Therapeutics Holdings, Inc.
Dave Mehalick, President and CEO
+1 724-934-6467

FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image